Stephen Harland

6.4k total citations · 1 hit paper
26 papers, 1.5k citations indexed

About

Stephen Harland is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Stephen Harland has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Surgery and 5 papers in Oncology. Recurrent topics in Stephen Harland's work include Prostate Cancer Treatment and Research (8 papers), Testicular diseases and treatments (7 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Stephen Harland is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Testicular diseases and treatments (7 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Stephen Harland collaborates with scholars based in United Kingdom, United States and Canada. Stephen Harland's co-authors include Arturo Molina, Christopher M. Haqq, Karim Fizazi, Howard I. Scher, Thian Kheoh, Christopher J. Logothetis, John Staffurth, Johann S. de Bono, Cora N. Sternberg and Paul N. Mainwaring and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Stephen Harland

26 papers receiving 1.4k citations

Hit Papers

Abiraterone acetate for treatment of metastatic castratio... 2012 2026 2016 2021 2012 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    2012 1.0k citations Karim Fizazi, Howard I. Scher et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen Harland United Kingdom 14 1.1k 509 330 320 235 26 1.5k
Martin Boegemann Germany 19 1.2k 1.0× 630 1.2× 388 1.2× 430 1.3× 131 0.6× 90 1.4k
Egils Vjaters Latvia 14 999 0.9× 345 0.7× 388 1.2× 227 0.7× 207 0.9× 51 1.4k
Marcello Tucci Italy 24 1.3k 1.2× 593 1.2× 369 1.1× 748 2.3× 191 0.8× 100 1.9k
Maria De Santis Austria 9 1.2k 1.1× 474 0.9× 253 0.8× 288 0.9× 109 0.5× 25 1.4k
Mario Eisenberger United States 14 981 0.9× 366 0.7× 247 0.7× 398 1.2× 93 0.4× 32 1.5k
Guilhem Roubaud France 19 1.1k 0.9× 238 0.5× 314 1.0× 702 2.2× 58 0.2× 132 1.6k
George Armitage Canada 7 1.0k 0.9× 225 0.4× 276 0.8× 565 1.8× 97 0.4× 14 1.4k
Ingela Franck Lissbrant Sweden 16 743 0.6× 121 0.2× 243 0.7× 367 1.1× 105 0.4× 41 1.3k
Martin Bögemann Germany 22 1.6k 1.4× 1.2k 2.3× 327 1.0× 510 1.6× 92 0.4× 86 1.9k
Sebastian Rogenhofer Germany 22 1.0k 0.9× 556 1.1× 381 1.2× 267 0.8× 28 0.1× 40 2.0k

Countries citing papers authored by Stephen Harland

Since Specialization
Citations

This map shows the geographic impact of Stephen Harland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Harland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Harland more than expected).

Fields of papers citing papers by Stephen Harland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Harland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Harland. The network helps show where Stephen Harland may publish in the future.

Co-authorship network of co-authors of Stephen Harland

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Harland. A scholar is included among the top collaborators of Stephen Harland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Harland. Stephen Harland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alifrangis, Constantine, Anand Sharma, Andrew Gogbashian, et al.. (2020). Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. European Journal of Cancer. 164. 105–113. 16 indexed citations
2.
Harland, Stephen, et al.. (2014). The natural history of bone metastases in castrate-resistant prostate cancer.. Journal of Clinical Oncology. 32(4_suppl). 239–239. 1 indexed citations
3.
Panagiotidis, Emmanouil, et al.. (2013). Myocardial Uptake of 99mTc-HDP and Reduced Perfusion on CT in Subacute Myocardial Infarction. Clinical Nuclear Medicine. 39(1). e117–e120. 3 indexed citations
4.
Harland, Stephen, John Staffurth, Arturo Molina, et al.. (2013). Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer. 49(17). 3648–3657. 68 indexed citations
5.
Tookman, Laura A., Athena Matakidou, Melissa Phillips, et al.. (2012). Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma. Acta Oncologica. 52(5). 987–993. 15 indexed citations
6.
Fizazi, Karim, Howard I. Scher, Arturo Molina, et al.. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 13(10). 983–992. 1036 indexed citations breakdown →
7.
8.
Büchler, Tomáš, Alex Freeman, & Stephen Harland. (2008). Contralateral intratubular germ cell neoplasia in a patient with testicular cancer. Nature Clinical Practice Urology. 5(5). 284–288. 2 indexed citations
9.
10.
Kalsi, Jas, Stephen Harland, & Mark Feneley. (2007). Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma. Expert Opinion on Drug Delivery. 5(1). 137–145. 6 indexed citations
11.
Freeman, Alex, et al.. (2007). Paraneoplastic Cushing’s syndrome in prostate cancer: a difficult management problem. British Journal of Urology. 101(4). 424–427. 23 indexed citations
12.
Anyamene, N., et al.. (2006). Transdermal oestrogen therapy as a second‐line hormonal intervention in prostate cancer: a bad experience. British Journal of Urology. 99(1). 53–55. 3 indexed citations
13.
Birtle, Alison, et al.. (2005). Tumour markers for managing men who present with metastatic prostate cancer and serum prostate‐specific antigen levels of <10 ng/mL. British Journal of Urology. 96(3). 303–307. 25 indexed citations
14.
15.
Rosen, Lee S., Stephen Harland, & Willem Oosterlinck. (2002). Broad Clinical Activity of Zoledronic Acid in Osteolytic to Osteoblastic Bone Lesions in Patients With a Broad Range of Solid Tumors. American Journal of Clinical Oncology. 25(6 Suppl 1). S19–S24. 20 indexed citations
16.
Harland, Stephen. (2000). Conundrum of the hereditary component of testicular cancer. The Lancet. 356(9240). 1455–1456. 6 indexed citations
17.
Harland, Stephen, Gordon E. Legge, & Andrew Luebker. (1998). Psychophysics of Reading. XVII. Low-Vision Performance with Four Types of Electronically Magnified Text. Optometry and Vision Science. 75(3). 183–190. 33 indexed citations
18.
Masters, John R., Barbara J. McDermott, Stephen Harland, Michael C. Bibby, & Paul M. Loadman. (1996). ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Cancer Chemotherapy and Pharmacology. 38(1). 59–64. 20 indexed citations
19.
Hartley, Janet M., et al.. (1993). Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 31(4). 328–332. 3 indexed citations
20.
Harland, Stephen, et al.. (1991). Carboplatin dose in combination chemotherapy for testicular cancer. European Journal of Cancer and Clinical Oncology. 27(6). 691–695. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Boegemann Breakdown of academic impact, for papers by Egils Vjaters Breakdown of academic impact, for papers by Marcello Tucci Breakdown of academic impact, for papers by Maria De Santis Breakdown of academic impact, for papers by Mario Eisenberger Breakdown of academic impact, for papers by Guilhem Roubaud Breakdown of academic impact, for papers by George Armitage Breakdown of academic impact, for papers by Ingela Franck Lissbrant Breakdown of academic impact, for papers by Martin Bögemann Breakdown of academic impact, for papers by Sebastian Rogenhofer
Rankless by CCL
2026